Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Centus Settles US Litigation Over Avastin

Agrees To Resolve Bevacizumab Patent Case With Genentech

Executive Summary

Centus Biotherapeutics and Roche’s Genentech have agreed to settle US patent litigation over the biosimilars firm’s FKB238 proposed bevacizumab rival to Avastin.

You may also be interested in...



Viatris And Biocon’s US Bevacizumab Hit By Indefinite Delay

Viatris and partner Biocon have seen FDA action on their application for a bevacizumab biosimilar rival to Avastin delayed by the need for a facility inspection, the timing of which is uncertain due to coronavirus-related restrictions.

AstraZeneca-Backed JV Sued By Genentech Over Avastin Biosimilar

With the US biosimilar Avastin market now more than a year old, another potential player, Centus Biotherapeutics, finds itself facing trial over its biosimilar candidate. The UK-based joint venture already boasts approval from the European Commission for its FKB238 product, Equidacent.

Centus Gets European Bevacizumab Approval

Centus Biotherapeutics has received formal European Commission approval for its Equidacent biosimilar rival to Avastin.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB150838

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel